Farallon Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Farallon Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-6,656,823	Closed	-$770M	–	188
2023 Q3	$770M	Sell	6,656,823 -265,000	-4%	-$28.5M	3.59%	4
2023 Q2	$712M	Buy	6,921,823 +1,502,000	+28%	+$158M	3.57%	4
2023 Q1	$592M	Buy	5,419,823 +1,724,900	+47%	+$191M	3.23%	5
2022 Q4	$420M	Buy	3,694,923 +1,914,700	+108%	+$159M	2.48%	8
2022 Q3	$110M	Buy	1,780,223 +687,063	+63%	+$48M	0.61%	50
2022 Q2	$0	Buy	+1,093,160	New	+$104M	﹤0.01%	343
2022 Q1	–	Sell	-1,396,217	Closed	-$136M	–	36
2021 Q4	$150M	Buy	1,396,217 +224,043	+19%	+$24.4M	0.75%	37
2021 Q3	$128M	Buy	1,172,174 +672,174	+134%	+$69.8M	0.6%	48
2021 Q2	$46.8M	Buy	+500,000	New	+$46M	0.19%	74
2020 Q4	–	Sell	-150,000	Closed	-$11.7M	–	166
2020 Q3	$11.7M	Buy	+150,000	New	+$10.3M	0.08%	99
2017 Q3	–	Sell	-745,000	Closed	-$8.84M	–	99
2017 Q2	$8.84M	Sell	745,000 -1,650,000	-69%	-$20.5M	0.09%	70
2017 Q1	$35.4M	Buy	2,395,000 +1,785,000	+293%	+$28.9M	0.39%	44
2016 Q4	$9.87M	Buy	+610,000	New	+$11.1M	0.11%	57
2014 Q1	–	Sell	-829,420	Closed	-$6.32M	–	106
2013 Q4	$6.32M	Sell	829,420 -1,393,651	-63%	-$7.52M	0.13%	63
2013 Q3	$7.45M	Hold	2,223,071	–	–	0.15%	58
2013 Q2	$5.47M	Buy	+2,223,071	New	+$5.33M	0.1%	65

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's HZNP Position: Q4 2023 in Review

Farallon Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 6,656,823 shares — an estimated $770M sold.

Farallon Capital Management first reported a position in HZNP in Q2 2013 and held it in 16 quarters. The position peaked at $770M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Farallon Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Farallon Capital Management sold 6,656,823 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $770M.
Farallon Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 16 quarters.
Farallon Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $770M in Q3 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Farallon Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.